- Jacobio's original innovative drug JAB-3312 obtained NMPA new drug clinical trial permission 2 days ago
- First Patient Enrolled for Phase 1 Clinical Study of JAB-3312 in US 2019-09-20
- The Successfully Initiation of Phase I Clinical Trial of JAB-3312 - Jacobio’s Second Innovative Drug 2019-09-04
- JAB-3312, Jacobio’s Second Innovative Drug, has Obtained FDA’s Approval for Clinical Study 2019-07-09
- Jacobio's Innovative Drug Approved for Phase IIa Clinical Study in Multiple Solid Tumors and Awarded Orphan Drug Designation for the Treatment of Esophageal Cancer by US FDA 2019-06-19
Jacobio Pharmaceuticals Co. Ltd., founded in 2015, is committed to the health development of human beings and the development of original new drugs with independent intellectual property rights in the world.
Senior Management Team
Innovative medicine leader
Our vision is to be a leader in innovative drugs, a promoter for new drug developers, and to provide more products and solutions for the health development of humans.